52P Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with non small-cell lung carcinoma (NSCLC): INTEPI, a multicentric retrospective study
Titel:
52P Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with non small-cell lung carcinoma (NSCLC): INTEPI, a multicentric retrospective study
Auteur:
Bilger, G. Girard, N. Doubre, H. Levra, M. Giaj Leprieur, E. Giroux Giraud, F. Decroisette, C. Livartowski, A. Massiani, M-A.